A novel mouse model of familial combined hyperlipidemia and atherosclerosis
In this study, we constructed a novel mouse model of familial combined hyperlipidemia through inserting a human ApoC3 transgene (hApoC3-Tg) into C57BL/6 J mice and injecting a gain-of-function variant of adeno-associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9)-D377Y concurrently with high cholesterol diet (HCD) feeding for 16 weeks. In the last 10 weeks, hApoC3-Tg mice were orally treated with a combination of atorvastatin (10 mg·kg-1·d-1) and fenofibrate (100 mg·kg-1·d-1). HCD-treated hApoC3-Tg mice demonstrated elevated levels of serum TG, total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-C). Oral administration of atorvastatin and fenofibrate significantly decreased the plaque sizes of en face aorta, aortic sinus and innominate artery accompanied by improved lipid profile and distribution. In summary, this novel mouse model is of considerable clinical relevance for evaluation of anti-atherosclerotic drugs by targeting both hypercholesterolemia and hypertriglyceridemia.PMID:38459255 | DOI:10.1038/s41401-024-01241-8
Source: Atherosclerosis - Category: Cardiology Authors: Mei-Jie Chen Yi-Tong Xu Lu Sun Zhi-Hua Wang Peter J Little Li Wang Xun-de Xian Jian-Ping Weng Suo-Wen Xu Source Type: research
More News: Adenoviruses | Atorvastatin Calcium | Cardiology | Cardiovascular | Cholesterol | Diets | Epidemiology | Fenofibrate | Genetics | Heart | Lipitor | Nutrition | Statin Therapy | Study | Tricor | Zivast